We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · May 17, 2022

Lenalidomide Promotes the Development of TP53-Mutated Therapy–Related Myeloid Neoplasms



Additional Info

Disclosure statements are available on the authors' profiles:

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
Blood 2022 May 05;[EPub Ahead of Print], AS Sperling, VA Guerra, JA Kennedy, Y Yan, JI Hsu, F Wang, AT Nguyen, PG Miller, ME McConkey, VA Quevedo Barrios, K Furudate, L Zhang, R Kanagal-Shamanna, J Zhang, LD Little, CE Gumbs, NG Daver, CD DiNardo, TM Kadia, F Ravandi, HM Kantarjian, G Garcia-Manero, A Futreal, BL Ebert, K Takahashi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading